Abstract
Mycoplasma genitalium infections of the urogenital tract are usually treated with azithromycin; however, for the past several years, rates of azithromycin treatment failure have increased. To document the occurrence and frequency of macrolide resistance-mediating mutations (MRMMs) in M. genitalium infections, we collected 894 M. genitalium-positive samples during April 2014-December 2017 and retrospectively tested them for MRMMs. We designated 67 samples collected within 6 weeks after a positive result as test-of-cure samples; of these, 60 were MRMM positive. Among the remaining 827 samples, the rate of MRMM positivity rose from 22.7% in 2014 and 22.3% in 2015 to 44.4% in 2016 but decreased to 39.7% in 2017. Because of these high rates of MRMMs in M. genitalium infections, we recommend that clinicians perform tests of cure after treatment and that researchers further explore the clinical consequences of this infection.
| Original language | English |
|---|---|
| Pages (from-to) | 1297-1303 |
| Number of pages | 7 |
| Journal | Emerging Infectious Diseases |
| Volume | 25 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2019 |
Keywords
- Adult
- Anti-Bacterial Agents/pharmacology
- Drug Resistance, Bacterial
- Female
- History, 21st Century
- Humans
- Macrolides/pharmacology
- Male
- Middle Aged
- Mycoplasma Infections/drug therapy
- Mycoplasma genitalium/drug effects
- Netherlands/epidemiology
- Public Health Surveillance
- Seasons
- Sexually Transmitted Diseases, Bacterial/epidemiology
- Young Adult